The Drugreporter Podcast10 Dec 2024

The EHRC 2024 Sessions: 4. Medication assisted therapies in EECA: status and progress | 6th European Harm Reduction Conference, Warsaw, 2024

The session provides an overview of the status and progress made in the EECA region to respond to the changing drug scene with medication assisted treatments that have developed in the last several years.
The session will provide an overview of the drug scene in EECA and its most recent changes.
It will highlight the case of Ukraine that managed to deliver life-saving OAT during the war and even more – introduce the innovation of providing long-acting depot buprenorphine (LADB) and expand OAT in prison settings.
The case of Kyrgyzstan introducing LADB for people who inject opioids within a pilot study to assess the feasibility as part of a UNITAID project will be presented.
Experience of providing ADHD medication to stimulant users within SoS project 2.0 will be shared in the context of Czech program on stimulant users medically-assisted treatment. The Czech Republic have been implementing methylphenidate based MAT to stimulant drug users for over 7 years in several settings - clinical and NGO drop-in centers. Ukraine has launched a pilot in 4 cities on the basis of narcological clinics that will allow to assess how the program helps stimulant users with ADHD cope with usage by means of treating ADHD medically, as well as providing psychosocial support aimed at reducing use, as well as the influence on the quality of life and the acceptability of the service in general.
Partners from Slovenia and Romania will share their experience of interesting approaches and developments in OAT provision, such as utilising mobile units and NGOs, a variety of medication options available and reaching solid coverage.
The session will also include representatives of the PWUD community; sharing their personal and community experience in relation to monitoring access and quality of medications, based on their recent experience of ECAT on OST.
Moderator: Maria Malakhova
Subsessions
Which factors facilitate or hinder the implementation of injectable opioid agonist treatment? A scoping review
December 02, 2024 4:00 PM – 4:10 PM
Fragile Grassroots Solidarities. On the Situation of Opioid Users in Poland.
December 02, 2024 4:10 PM – 4:20 PM
Introducing Long-Acting Depot Buprenorphine in Kyrgyzstan: A Feasibility Study
December 02, 2024 4:20 PM – 4:30 PM

Drugreporter (EN): https://www.drugreporter.net/ Facebook (HU): https://www.facebook.com/drogriporter/ Facebook (EN): https://www.facebook.com/drugreporter/ Instagram (HU): https://www.instagram.com/drogriporter/ Instagram (EN): https://www.instagram.com/rrfdrugreporter/ X.com (EN): https://x.com/RRFdrugreporter TikTok (EN): https://www.tiktok.com/@drugreporter_rrf/ Bluesky (EN): https://www.bsky.app/profile/drugreporter.bsky.social/ A Jogriporter Alapítvány: https://www.jogriporter.hu/ The Rights Reporter Foundation: https://www.rightsreporter.net/

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(123)

ROBERT JESSE | The value of community can help psychedelics move into mainstream culture

At ICPR 2024, we talked to Robert Jesse, from the Johns Hopkins University, about mystical experiences with psychedelics, their spiritual and cultural dimensions, and the value of community in support...

18 Sep 27min

LEONIE SCHNEIDER, BSC & IAN ROULLIER, MA | We need compassionate access to psychedelic treatment

At ICPR 2024, we talked to Leonie Schneider and Ian Roullier, co-founders and co-directors of the Psychedelic Participant Advocacy Network (PsyPAN) in the UK, about why patient voices matter in the de...

18 Sep 21min

Psychedelics: Saving Lives and Transforming Health Care – Interview with Tomáš Páleníček, MD, PhD

Psychedelic research in the Czech Republic has a long and distinguished history. At ICPR 2026, we spoke with psychiatrist and neuroscientist Tomáš Páleníček about clinical research, altered states of ...

18 Sep 26min

WIM VAN DEN BRINK | Psychedelics help reduce compulsive thinking, such as craving in drug addiction

At ICPR 2024, we talked to Wim van den Brink, MD, PhD, Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam, about the potential of psychedelics to reduce comp...

31 Aug 29min

Psychedelics: The State of the Science in 2026 – Interview with Sandeep Nayak, MD

What actually makes psychedelic therapy work? Is it the drug, the therapeutic setting, or the human relationship between therapist and participant? At ICPR 2026, we spoke with psychiatrist and researc...

31 Aug 33min

NICOLAS LANGLITZ, MD, PHD: You have to find a space for these wild psychedelics in a rule governed world

At ICPR 2024, we talked to anthropologist and author Nicolas Langlitz about the current hype around psychedelics, their place in medicine and culture, and why he sees them as holding the promise of mo...

31 Aug 29min

Psychedelics and the Female experience – Interview with Grace Blest-Hopley, PhD

Women make up more than half of the population, yet they remain significantly underrepresented in psychedelic research. At ICPR 2026, we spoke with neuroscientist Grace Blest-Hopley about the gender g...

31 Aug 31min

MARC B. AIXALÀ: Bad trips can transform into potentially positive outcomes

At ICPR 2024, we talked to psychologist and psychotherapist Marc B. Aixalà about how so-called “bad trips” can be reframed as difficult but potentially transformative experiences, and the importance o...

26 Maj 16min